Wattana Karnpaet PCL

Wattana Karnpaet PCL maintains a strong liquidity position, with a current ratio of 1.5 and cash and equivalents amounting to 44,969,670 THB. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet short-term obligations without external financing.

Profitability metrics show a return on equity (ROE) of 1.95% and a return on assets (ROA) of 1.52%, which are below the industry median for healthcare facilities and services. The company's operating margin is 10.57%, and its net margin is 8.06%, both of which are in line with the sector average.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes.

Looking ahead, the company is projected to maintain stable revenue growth, with a year-over-year increase of 3.5% in the current fiscal year and 4.2% in the next fiscal year. This growth is supported by a consistent free cash flow generation of 15,503,160 THB and a capital expenditure of -5,404,740 THB, indicating a focus on maintaining operations rather than aggressive expansion.

Risk factors for the company are minimal, with low liquidity and dilution risk. The debt-to-equity ratio is 0.07, and there are no immediate filing-based liquidity or dilution flags. The company has not issued new shares in the past year, and there is no indication of near-term dilution pressure.

Recent filings and transcripts do not indicate any material changes in the company's operations or strategic direction. The company continues to focus on its core pharmaceutical and healthcare services, with no disclosed plans for new product lines or geographic expansion.